Clinical Trials Logo

Filter by:
NCT ID: NCT02308020 Completed - Breast Cancer Clinical Trials

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

Start date: April 20, 2015
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.

NCT ID: NCT02307838 Completed - Clinical trials for Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Long-term Follow-up of Fingolimod Phase II Study Patients

ACROSS
Start date: June 2014
Phase: Phase 4
Study type: Interventional

This study aims to collect follow-up data on approximately 90% of patients who were randomized and received one dose of study drug in FTY720D2201. No study drug is given or required. Patients will be required to be assessed at one or two visits, preferably at the original study site, but the option to be interviewed via phone or seen at home is provided. Information will also be gathered on deceased patients. Assessments will be performed only once within an 8 week period and include medical history, Multiple Sclerosis (MS) and Multiple Sclerosis Disease Modifying Therapy (MS DMT) history, Expanded Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), Multiple Sclerosis Functional Composite (MSFC).

NCT ID: NCT02307513 Completed - Behçet's Syndrome Clinical Trials

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Start date: December 30, 2014
Phase: Phase 3
Study type: Interventional

The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).

NCT ID: NCT02307500 Completed - Ovarian Cancer Clinical Trials

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

RESOUND
Start date: December 2014
Phase: Phase 2
Study type: Interventional

This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic carcinoma, who have progressed after standard therapy.

NCT ID: NCT02307279 Completed - Obesity Clinical Trials

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Start date: November 2014
Phase: N/A
Study type: Interventional

This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.

NCT ID: NCT02307253 Completed - Abdominal Neoplasms Clinical Trials

EUS GUIDED Transduodenal Biopsy Using the 19G Flex

NIFLEX
Start date: June 2013
Phase: N/A
Study type: Interventional

This study evaluates the feasibility, safety and accuracy of a 19 gauge (19G) needle in nitinol in the performance of endoscopic ultrasound (EUS) guided transduodenal biopsy for the acquisition of samples for histologic analysis. Patients with lesions that can be approached only from the duodenum will be prospectively enrolled.

NCT ID: NCT02307227 Completed - Breast Neoplasms Clinical Trials

Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

Start date: April 2006
Phase: Phase 2
Study type: Interventional

Prospective, monoinstitutional, phase II study. Patients with HER 2 positive locally advanced breast cancer will be treated with 3 initial cycles (12 weeks) of trastuzumab plus paclitaxel and then if responding further 12 weeks and then with surgical resection, patients with HER2 negative breast carcinoma will be treated with 4 cycles (12 weeks) of epirubicin and taxotere. If responding 4 more cycles (12 weeks). Patients progressing will be treated depending on physician's and patient's preference

NCT ID: NCT02306109 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)

ermoSla
Start date: January 2015
Phase: N/A
Study type: Interventional

ErmoSLA is a multicentric, randomized, controlled trial to compare effects of an "intensive" or "standard" motor rehabilitation treatment on motor disability in people with ALS

NCT ID: NCT02305810 Completed - Clinical trials for Pancreatic Neuroendocrine Tumour Metastatic

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

Start date: September 2013
Phase: Phase 2
Study type: Interventional

Everolimus represents an approved therapy for patients with advanced well/moderately differentiated pancreatic NETs. Although some patients could benefit from this drug in terms of long-term tumor growth control, others are resistant upfront or become resistant during treatment. Therefore, it is crucial to detect some biological factors which can help to identify the responsive tumors. Given that Everolimus is a biological agent and its mechanism of action can be partially directed towards angiogenesis its effects can be studied on different levels and with different methods. Upfront and early surrogate predictive markers of activity/efficacy can be studied on tumor tissue, tumor imaging, and peripheral blood. mTOR pathways alterations, circulating endothelial cells, and other circulating angoigenic factors will be correlated with clinical outcome. Tumor perfusion and circulating markers will be studied also as markers of response compared with the morphological imaging.

NCT ID: NCT02305108 Completed - Osteoarthritis Clinical Trials

Fascial Manipulation in Patients With Hip Osteoarthritis

manifahip
Start date: June 2014
Phase: N/A
Study type: Interventional

The study will test the efficacy of the treatment of soft tissues for osteoarthritis patients that are waiting for total hip arthroplasty. The fascial manipulation provides a deep pressure of specific points of the muscle fascia. The aims of this treatment are the improve of pain before the surgery and the improve of functional performance after the surgery.